PL368970A1 - Compounds effecting glucokinase - Google Patents

Compounds effecting glucokinase

Info

Publication number
PL368970A1
PL368970A1 PL02368970A PL36897002A PL368970A1 PL 368970 A1 PL368970 A1 PL 368970A1 PL 02368970 A PL02368970 A PL 02368970A PL 36897002 A PL36897002 A PL 36897002A PL 368970 A1 PL368970 A1 PL 368970A1
Authority
PL
Poland
Prior art keywords
glucokinase
compounds effecting
compounds
effecting glucokinase
effecting
Prior art date
Application number
PL02368970A
Other languages
English (en)
Polish (pl)
Inventor
Scott Boyd
Peter William Rodney Caulkett
Rodney Brian Hargreaves
Suzanne Saxon Bowker
Roger James
Craig Johnstone
David Clifford Jones
Darren Mckerrecher
Michael Howard Block
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL368970A1 publication Critical patent/PL368970A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL02368970A 2001-08-17 2002-08-15 Compounds effecting glucokinase PL368970A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102764A SE0102764D0 (sv) 2001-08-17 2001-08-17 Compounds

Publications (1)

Publication Number Publication Date
PL368970A1 true PL368970A1 (en) 2005-04-04

Family

ID=20285065

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368970A PL368970A1 (en) 2001-08-17 2002-08-15 Compounds effecting glucokinase

Country Status (31)

Country Link
US (3) US7390908B2 (OSRAM)
EP (12) EP1661563B1 (OSRAM)
JP (2) JP3987829B2 (OSRAM)
KR (1) KR100920439B1 (OSRAM)
CN (4) CN101584691A (OSRAM)
AR (1) AR037898A1 (OSRAM)
AT (11) ATE397927T1 (OSRAM)
AU (1) AU2002321462B2 (OSRAM)
BR (1) BR0212008A (OSRAM)
CA (1) CA2457410C (OSRAM)
CO (1) CO5560563A2 (OSRAM)
CY (5) CY1105746T1 (OSRAM)
DE (11) DE60228897D1 (OSRAM)
DK (5) DK1661563T3 (OSRAM)
ES (10) ES2308609T3 (OSRAM)
HU (1) HUP0401213A3 (OSRAM)
IL (2) IL160219A0 (OSRAM)
IS (1) IS7150A (OSRAM)
MX (1) MXPA04001500A (OSRAM)
MY (1) MY146279A (OSRAM)
NO (1) NO20040686L (OSRAM)
NZ (1) NZ531193A (OSRAM)
PL (1) PL368970A1 (OSRAM)
PT (5) PT1661569E (OSRAM)
RU (1) RU2329043C9 (OSRAM)
SE (1) SE0102764D0 (OSRAM)
SI (5) SI1661569T1 (OSRAM)
TW (1) TWI333855B (OSRAM)
UA (1) UA83182C2 (OSRAM)
WO (1) WO2003015774A1 (OSRAM)
ZA (1) ZA200401015B (OSRAM)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1541564A1 (en) 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
JP2004123732A (ja) * 2002-09-10 2004-04-22 Takeda Chem Ind Ltd ５員複素環化合物
RU2005113713A (ru) 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
AU2004220234C1 (en) 2003-02-13 2013-01-17 Msd K.K. Novel 2-pyridinecarboxamide derivatives
UA81468C2 (en) 2003-02-26 2008-01-10 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives
DE602004016992D1 (de) * 2003-05-02 2008-11-20 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
DE602004021933D1 (de) * 2003-05-02 2009-08-20 Elan Pharm Inc 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3-carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen
ATE390922T1 (de) * 2003-06-20 2008-04-15 Hoffmann La Roche 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
ES2222822B1 (es) * 2003-07-28 2005-12-16 Laboratorios Farmaceuticos Rovi, S.A. Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos.
WO2005046683A1 (en) 2003-10-07 2005-05-26 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
US20080312207A1 (en) * 2004-02-18 2008-12-18 Craig Johnstone Compounds
ES2322709T3 (es) * 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2005095417A1 (en) 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
ATE524479T1 (de) 2004-04-02 2011-09-15 Novartis Ag Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
RU2403246C2 (ru) * 2004-06-05 2010-11-10 Астразенека Аб Гетероарилбензамидные производные для применения в качестве активаторов глюкокиназы (glk) в лечении диабета
KR100739367B1 (ko) * 2004-07-14 2007-07-16 크리스탈지노믹스(주) 설파마이드 유도체 및 이를 함유하는 지방대사 촉진용약학적 조성물
AU2005293343B2 (en) 2004-10-16 2009-03-19 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
AU2006250354A1 (en) * 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
GB0510852D0 (en) * 2005-05-27 2005-07-06 Astrazeneca Ab Chemical compounds
EP1910350A1 (en) * 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
RU2415141C2 (ru) * 2005-07-09 2011-03-27 Астразенека Аб Производные гетероарилбензамида для применения в качестве активаторов glk в лечении диабета
BRPI0622261A2 (pt) * 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
GB0514173D0 (en) * 2005-07-09 2005-08-17 Astrazeneca Ab Chemical compounds
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
RU2008112198A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
JP5198280B2 (ja) 2005-11-17 2013-05-15 イーライ リリー アンド カンパニー グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
JP5190448B2 (ja) * 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
EP2019824A2 (en) * 2006-04-28 2009-02-04 Transtech Pharma, Inc. Benzamide glucokinase activators
JP2009535319A (ja) * 2006-04-28 2009-10-01 トランステック ファーマ，インコーポレイティド ベンズアミドグルコキナーゼ活性化剤
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
KR101264820B1 (ko) 2006-08-24 2013-05-22 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
WO2008031534A1 (en) 2006-09-11 2008-03-20 Syngenta Participations Ag Insecticidal compounds
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
CN101563330B (zh) * 2006-10-26 2012-06-27 阿斯利康(瑞典)有限公司 作为葡糖激酶(glk)激活剂的苯甲酰氨基杂环化合物
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
EP2096111A1 (en) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
CA2672631A1 (en) * 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
RU2009121756A (ru) * 2006-12-21 2011-01-27 Астразенека Аб (Se) Новое кристаллическое соединение, полезное в качестве активатора глюкокиназы (glk)
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CN101622231B (zh) * 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8299115B2 (en) 2007-06-08 2012-10-30 Debnath Bhuniya Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
JP2010529203A (ja) * 2007-06-11 2010-08-26 ブリストル−マイヤーズ スクイブ カンパニー １，３−ジヒドロキシ置換フェニルアミドグルコキナーゼ活性化剤
MX2010001358A (es) * 2007-08-03 2010-04-09 Romark Lab Lc Compuestos de tiazolida sustituidos con alquilsulfonilo.
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
TW200922582A (en) * 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
CA2700783C (en) * 2007-10-08 2015-03-17 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
MX2010003759A (es) * 2007-10-09 2010-04-21 Merck Patent Gmbh Derivados de piridina utiles como activadores de glucocinasa.
US8236824B2 (en) * 2007-10-09 2012-08-07 MERCK Patent Gesellschaft mit beschränkter Haftung N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CN102099357B (zh) 2008-04-23 2014-07-02 里格尔药品股份有限公司 用于治疗代谢障碍的甲酰胺化合物
KR101006311B1 (ko) * 2008-06-27 2011-01-06 김정이 온수를 이용한 황토 온열매트 및 그 제조방법
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR20110052676A (ko) 2008-08-04 2011-05-18 아스트라제네카 아베 피라졸로[3,4]피리미딘-4-일 유도체 및 당뇨병 및 비만을 치료하기 위한 이의 용도
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
US8214916B2 (en) 2009-01-26 2012-07-03 Nanoink, Inc. Large area, homogeneous array fabrication including leveling with use of bright spots
AU2010206594A1 (en) 2009-01-26 2011-07-28 Nanoink, Inc. Large area, homogeneous array fabrication including homogeneous substrates
KR20110119666A (ko) 2009-01-26 2011-11-02 나노잉크, 인크. 기판 온도 조절을 포함하는 넓은 면적의 균일한 어레이 제작
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
AP3074A (en) 2009-05-12 2014-12-31 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CA2968113C (en) 2009-06-26 2019-05-14 Romark Laboratories L.C. Compounds and methods for treating influenza
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
JP2013500961A (ja) * 2009-07-31 2013-01-10 カディラ ヘルスケア リミテッド グルコキナーゼ（ｇｋ）アクチベーターとしての置換ベンズアミド誘導体
US20120178765A1 (en) * 2009-09-22 2012-07-12 Yuhan Corporation Novel glucokinase activators and processes for the preparation thereof
PL2480539T3 (pl) * 2009-09-25 2013-11-29 Bayer Cropscience Ag N-(1,2,5-oksadiazol-3-ilo)benzamidy i ich zastosowanie jako herbicydy
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013522294A (ja) * 2010-03-18 2013-06-13 タケダ カリフォルニア インコーポレイテッド ２−アミノ−５−フルオロチアゾールの製造プロセス
WO2011135355A1 (en) 2010-04-29 2011-11-03 Astrazeneca Ab 3-{ [5 -(azetidin-1-ylcarbonyl)pyrazin-2 -yl] oxy} -5-{ [(1s) -2 -hydroxy- 1 -methylethyl]oxy} -n- (5 -methylpyrazin-2-) benzamid monohydrate
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5769326B2 (ja) * 2010-10-19 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｈｏキナーゼ阻害薬
MX2013004724A (es) * 2010-11-01 2013-08-29 Romark Lab Lc Compuestos de tiazolida alquilsulfinilo-sustituidos.
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
US20150057220A1 (en) 2012-04-16 2015-02-26 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP6226978B2 (ja) 2012-07-13 2017-11-08 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN102942541B (zh) * 2012-12-04 2014-07-23 西北师范大学 一种受体化合物及其合成和在比色检测氟离子中的应用
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
WO2014172044A1 (en) * 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104672219A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一类含葡萄糖酰胺结构的葡萄糖激酶活化剂及其用途
CN104672218A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 含葡萄糖酰胺结构的葡萄糖激酶活化剂、制备方法及其在治疗2型糖尿病上的用途
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
US11345676B2 (en) * 2017-03-27 2022-05-31 Pharmakea, Inc. Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN110606831A (zh) * 2018-06-14 2019-12-24 上海度德医药科技有限公司 一种Iclaprim的新中间体及其制备方法和应用
CN109879818A (zh) * 2019-04-04 2019-06-14 安徽丰乐农化有限责任公司 N-(4,6-二甲氧基嘧啶-2-基)-4-甲砜基-2-硝基苯甲酰胺的合成方法
EP3986559A1 (en) * 2019-06-24 2022-04-27 BenevolentAI Bio Limited New compounds and methods
KR102138149B1 (ko) * 2019-08-29 2020-07-27 솔브레인 주식회사 박막 형성용 성장 억제제, 이를 이용한 박막 형성 방법 및 이로부터 제조된 반도체 기판
CN114591192B (zh) * 2020-12-04 2024-06-21 江西仰立新材料有限公司 一种n-环丙甲基苯胺类化合物的制备方法
CN119639021B (zh) * 2024-12-27 2025-10-21 常州大学 一类树状分子超分子凝胶因子及其应用

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
FR1526074A (fr) 1967-03-22 1968-05-24 Rech S Ind S O R I Soc D Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation
FR2088019A1 (en) 1970-05-08 1972-01-07 Rabot Ets David Esters of 2 and 6-substituted nicotinic acids - with vasomotor active
GB1352415A (en) 1970-05-03 1974-05-08 Boots Co Ltd Esters of substituted nicotine acids
CS173097B1 (OSRAM) 1972-12-01 1977-02-28
GB1400540A (en) 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
JPS5734314B2 (OSRAM) 1973-12-22 1982-07-22
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
GB1588242A (en) 1977-10-28 1981-04-23 May & Baker Ltd N-(tetrazol-5-yl)-salicylamide derivatives
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
JPS5721320A (en) 1980-07-11 1982-02-04 Chugai Pharmaceut Co Ltd Blood sugar level depressing agent
JPS5775962A (en) 1980-10-29 1982-05-12 Shionogi & Co Ltd 2-alkoxybenzamide derivative
FR2493848B2 (fr) 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
JPS59139357A (ja) 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
JPS61205937A (ja) 1985-03-09 1986-09-12 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
JPS62158252A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンベンズアミド誘導体
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
DE3822449A1 (de) 1988-07-02 1990-01-04 Henkel Kgaa Oxidationshaarfaerbemittel mit neuen kupplern
JPH03181465A (ja) 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
JPH04300832A (ja) 1991-03-29 1992-10-23 Tsumura & Co ２，４−ジアミノ−１，３，５−トリアジン誘導体を有　　　　　　　　　　　効成分とするロイコトリエン拮抗剤
JPH04300874A (ja) 1991-03-29 1992-10-23 Tsumura & Co 新規２，４−ジアミノ−１，３，５−トリアジン誘導体
US5466715A (en) 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
JPH0627025A (ja) 1992-07-06 1994-02-04 Toto Ltd 分子認識機能膜及びこれを用いたセンサー
WO1994004525A1 (en) 1992-08-20 1994-03-03 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds as oxytocin and vasopressin antagonists
CA2400368A1 (en) 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
DK0706514T3 (da) 1993-08-24 1999-08-02 Medivir Ab Forbindelser og fremgangsmåder til inhibering af HIV og relaterede vira
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
PT714898E (pt) 1994-06-21 2002-04-29 Otsuka Pharma Co Ltd Derivado de pirazolo¬1,5-a|pirimidina
US5661153A (en) 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5792109A (en) * 1994-09-01 1998-08-11 Leland L. Ladd Irrigation pump and system
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
JPH08143565A (ja) 1994-11-16 1996-06-04 Fujisawa Pharmaceut Co Ltd ベンズアミド化合物
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
KR100432843B1 (ko) 1994-12-20 2004-10-14 에프. 호프만-라 로슈 아게 아릴-및헤트아릴-설폰아미드유도체,이들의제조방법및이들의엔도텔린길항제로서의용도
US5536718A (en) 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5532235A (en) 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5700796A (en) 1995-01-17 1997-12-23 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5696112A (en) 1995-01-17 1997-12-09 American Cyanamid Company Fused heterocyclic azepines as vasopressin antagonists
JPH08301760A (ja) 1995-05-10 1996-11-19 Shiseido Co Ltd 皮膚外用剤
AU699008B2 (en) 1995-05-18 1998-11-19 Zeria Pharmaceutical Co., Ltd. Aminothiazole derivative, medicament containing the same, and intermediate for preperation of said compound
JP3168915B2 (ja) 1995-05-25 2001-05-21 田辺製薬株式会社 医薬組成物
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
JP3735741B2 (ja) 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
IL126318A (en) 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
KR100298523B1 (ko) 1996-06-06 2001-09-06 오쓰카 요시미쓰 아미드유도체
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
JPH10212271A (ja) 1997-01-31 1998-08-11 Zeria Pharmaceut Co Ltd Ｎ−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体
CA2319672C (en) 1997-02-07 2011-01-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JPH10338658A (ja) 1997-04-08 1998-12-22 Hoechst Marion Roussel Kk レチノイド作用調節剤
JPH1129480A (ja) 1997-05-12 1999-02-02 Otsuka Pharmaceut Factory Inc 縮環ピリミジン誘導体を含有する医薬組成物
EP1000932B9 (en) 1997-06-27 2005-12-28 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
EP0995742A4 (en) 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6114483A (en) 1997-08-27 2000-09-05 E. I. Du Pont De Nemours And Company Polymerization of olefins
JPH11171848A (ja) 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69801590T2 (de) 1997-10-22 2002-07-11 Astrazeneca Ab, Soedertaelje Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren
JP4398585B2 (ja) 1997-11-12 2010-01-13 有限会社ケムフィズ レチノイドレセプター作用剤
DK1042320T3 (da) 1997-11-21 2002-05-13 Astrazeneca Uk Ltd Nye forbindelser, som er P2-purinoceptor-7-transmembran (TM) G-proteinkoblede receptorantagonister
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
IL135536A0 (en) 1997-12-19 2001-05-20 Schering Ag Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
JP3937367B2 (ja) 1998-02-05 2007-06-27 株式会社大塚製薬工場 一酸化窒素合成酵素阻害剤
JPH11292879A (ja) * 1998-04-08 1999-10-26 Otsuka Pharmaceut Factory Inc カルボキサミド誘導体
DE19816780A1 (de) 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
DE19830431A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
EP1140903B1 (en) * 1998-12-23 2004-08-04 Eli Lilly And Company Aromatic amides
EP1150955A2 (en) 1999-02-04 2001-11-07 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CN1151140C (zh) * 1999-03-29 2004-05-26 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
SG148834A1 (en) 1999-06-30 2009-01-29 Japan Tobacco Inc Compounds for the modulation of ppary activity
AR032130A1 (es) 1999-08-13 2003-10-29 Vertex Pharma Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto
JP2003508382A (ja) 1999-08-27 2003-03-04 スージェン・インコーポレーテッド リン酸模倣体およびホスファターゼ阻害剤を用いる治療方法
GB9921684D0 (en) 1999-09-15 1999-11-17 Zeneca Ltd Assays
MX226123B (es) * 1999-09-17 2005-02-07 Millennium Pharm Inc Benzamidas e inhibidores del factor xa relacionadas.
JP4831907B2 (ja) 1999-10-08 2011-12-07 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
KR20020047321A (ko) 1999-11-04 2002-06-21 오르토-맥네일 파마슈티칼, 인코퍼레이티드 바소프레신 길항제로서의 비펩티드 치환 벤조티아제핀
WO2001035950A2 (en) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics and methods for treating inflammatory bowel disease
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
EP1132381A1 (en) 2000-03-08 2001-09-12 Cermol S.A. Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
EP1280801B1 (en) 2000-05-03 2005-09-07 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
CA2407416C (en) * 2000-05-03 2006-07-18 Paige Erin Mahaney Alkynyl phenyl heteroaromatic glucokinase activators
EP1282611B1 (en) 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
DK1283830T3 (da) 2000-05-08 2008-08-25 Hoffmann La Roche Para-amin-substituerede phenylamidglucokinase-aktivatorer
PL214670B1 (pl) 2000-06-28 2013-08-30 Amgen Inc Chinolinylowe modulatory PPAR-gamma, kompozycja je zawierajaca, zwiazek do zastosowania w leczeniu lub zapobieganiu chorobom oraz zastosowanie zwiazku do wytwarzania leku
ATE297907T1 (de) 2000-07-20 2005-07-15 Hoffmann La Roche Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase- aktivatoren
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
DE60118225T2 (de) 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
WO2002026718A2 (en) 2000-09-29 2002-04-04 Millennium Pharmaceutical, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
AU2002211281A1 (en) 2000-09-29 2002-04-08 Millenium Pharmaceuticals, Inc. Quaternary amidino based inhibitors of factor xa
KR20030067675A (ko) 2000-10-05 2003-08-14 후지사와 야꾸힝 고교 가부시키가이샤 벤자미드 화합물
EP1336605B1 (en) 2000-11-22 2006-04-12 Astellas Pharma Inc. Substituted phenol derivatives or salts thereof as inhibitors of coagulation factor x
JP4109111B2 (ja) 2000-12-06 2008-07-02 エフ．ホフマン−ラ ロシュ アーゲー 縮合複素環式芳香族グルコキナーゼアクチベーター
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
EP1344525A4 (en) 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
DE60221505D1 (de) 2001-03-30 2007-09-13 Millennium Pharm Inc FAKTOR Xa BENZAMIDIN INHIBITOREN
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
RU2315746C2 (ru) 2001-08-09 2008-01-27 Оно Фармасьютикал Ко., Лтд. Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента
TWI312274B (en) 2001-08-13 2009-07-21 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005527472A (ja) 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
TW200724033A (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
CN1582281A (zh) 2001-10-01 2005-02-16 大正制药株式会社 Mch受体拮抗剂
EP1453541A1 (en) 2001-12-03 2004-09-08 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
WO2003048152A2 (en) 2001-12-05 2003-06-12 Tularik Inc. Inflammation modulators
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
BR0215212A (pt) 2001-12-21 2004-12-07 Novo Nordisk As Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
CA2488161A1 (en) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
WO2003095438A1 (en) 2002-04-26 2003-11-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
WO2003097824A1 (en) 2002-05-16 2003-11-27 Banyu Pharmaceutical Co., Ltd. Crystal of glucokinase protein, and method for drug design using the crystal
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
RU2005113713A (ru) 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
CA2509086C (en) 2003-01-06 2012-08-21 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
AU2004220234C1 (en) 2003-02-13 2013-01-17 Msd K.K. Novel 2-pyridinecarboxamide derivatives
UA81468C2 (en) 2003-02-26 2008-01-10 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
WO2005063738A1 (ja) 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd 新規２－へテロアリール置換ベンズイミダゾール誘導体
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
US20080312207A1 (en) 2004-02-18 2008-12-18 Craig Johnstone Compounds
ES2322709T3 (es) 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
WO2005090332A1 (ja) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd 置換キナゾリン又はピリドピリミジン誘導体
WO2005095417A1 (en) 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
ATE524479T1 (de) 2004-04-02 2011-09-15 Novartis Ag Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
NZ550567A (en) 2004-04-21 2010-07-30 Prosidion Ltd Tri(cyclo) substituted amide compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US20080026987A1 (en) 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
AU2005271016A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
AU2005293343B2 (en) 2004-10-16 2009-03-19 Astrazeneca Ab Process for making phenoxy benzamide compounds
EP1834256B1 (en) 2004-12-24 2008-12-17 Telecom Italia S.p.A. Method of optimising web page access in wireless networks
ATE524467T1 (de) 2005-04-25 2011-09-15 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren
US20110059941A1 (en) 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP1910350A1 (en) 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
BRPI0622261A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1915367A1 (en) 2005-08-09 2008-04-30 AstraZeneca AB Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20090105263A1 (en) 2005-09-16 2009-04-23 Peter William Rodney Caulkett Heterobicyclic compounds as glucokinase activators
JP2009513711A (ja) 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
RU2009121756A (ru) 2006-12-21 2011-01-27 Астразенека Аб (Se) Новое кристаллическое соединение, полезное в качестве активатора глюкокиназы (glk)

Also Published As

Publication number Publication date
RU2329043C2 (ru) 2008-07-20
CA2457410A1 (en) 2003-02-27
AR037898A1 (es) 2004-12-22
ATE397927T1 (de) 2008-07-15
CY1105746T1 (el) 2010-12-22
BR0212008A (pt) 2004-09-28
EP1420784B1 (en) 2006-04-19
WO2003015774A1 (en) 2003-02-27
HK1093429A1 (en) 2007-03-02
US20050080106A1 (en) 2005-04-14
ATE397926T1 (de) 2008-07-15
DE60228770D1 (de) 2008-10-16
DE60210782T2 (de) 2007-05-10
EP1669069B1 (en) 2008-09-10
ES2312051T3 (es) 2009-02-16
DK1529530T5 (da) 2009-11-23
HK1076042A1 (en) 2006-01-06
EP1661567B1 (en) 2008-06-11
EP1661569B1 (en) 2008-06-11
EP1661563B1 (en) 2008-05-28
ES2307239T3 (es) 2008-11-16
DK1669068T3 (da) 2008-09-22
US20080207636A1 (en) 2008-08-28
ES2308609T3 (es) 2008-12-01
ATE406891T1 (de) 2008-09-15
ATE323487T1 (de) 2006-05-15
CA2457410C (en) 2011-09-27
ATE407672T1 (de) 2008-09-15
DE60219698T3 (de) 2010-02-25
SI1661563T1 (sl) 2008-10-31
DE60228897D1 (de) 2008-10-23
AU2002321462B2 (en) 2007-09-20
EP1669069A1 (en) 2006-06-14
ES2307238T3 (es) 2008-11-16
DE60210782D1 (de) 2006-05-24
ES2285341T7 (es) 2010-03-31
EP1674097A1 (en) 2006-06-28
CY1108267T1 (el) 2014-02-12
US7951830B2 (en) 2011-05-31
DE60227119D1 (de) 2008-07-24
EP1529530A1 (en) 2005-05-11
DE60228143D1 (de) 2008-09-18
PT1529530E (pt) 2006-11-30
EP1420784A1 (en) 2004-05-26
JP3987829B2 (ja) 2007-10-10
ES2306300T3 (es) 2008-11-01
DE60219698D1 (de) 2007-05-31
DE60213678D1 (de) 2006-09-14
HK1090839A1 (en) 2007-01-05
CN100577163C (zh) 2010-01-06
US20090227592A1 (en) 2009-09-10
DK1529530T3 (da) 2006-11-13
PT1661563E (pt) 2008-07-31
JP2005525291A (ja) 2005-08-25
EP1529530B3 (en) 2009-09-02
EP1661563A1 (en) 2006-05-31
HK1079692A1 (en) 2006-04-13
HK1089958A1 (en) 2006-12-15
DK1661563T3 (da) 2008-08-25
EP1695705B1 (en) 2008-08-06
EP1661568A1 (en) 2006-05-31
UA83182C2 (en) 2008-06-25
ZA200401015B (en) 2005-05-06
PT1669068E (pt) 2008-08-20
EP1661568B1 (en) 2008-09-03
EP1661569A1 (en) 2006-05-31
DE60213678T2 (de) 2007-08-09
ES2309862T3 (es) 2008-12-16
SI1568367T1 (sl) 2007-08-31
SI1661569T1 (sl) 2008-10-31
CY1107683T1 (el) 2013-04-18
CY1108254T1 (el) 2014-02-12
HK1090292A1 (en) 2006-12-22
EP1669068B1 (en) 2008-06-11
IS7150A (is) 2004-02-13
HK1089960A1 (en) 2006-12-15
HK1064598A1 (en) 2005-02-04
TW200911238A (en) 2009-03-16
HK1089966A1 (en) 2006-12-15
NO20040686L (no) 2004-02-17
US7524957B2 (en) 2009-04-28
ES2270263T3 (es) 2007-04-01
DE60227121D1 (de) 2008-07-24
ATE397929T1 (de) 2008-07-15
RU2004104333A (ru) 2005-03-27
IL160219A0 (en) 2004-07-25
PT1568367E (pt) 2007-06-28
US7390908B2 (en) 2008-06-24
CN101704797A (zh) 2010-05-12
ATE396720T1 (de) 2008-06-15
SE0102764D0 (sv) 2001-08-17
CN101584691A (zh) 2009-11-25
EP1568367B3 (en) 2009-09-02
CO5560563A2 (es) 2005-09-30
EP1661567A1 (en) 2006-05-31
ES2307237T3 (es) 2008-11-16
DE60227120D1 (de) 2008-07-24
ATE359781T1 (de) 2007-05-15
ATE397928T1 (de) 2008-07-15
DE60227122D1 (de) 2008-07-24
MY146279A (en) 2012-07-31
TWI333855B (en) 2010-12-01
NZ531193A (en) 2005-07-29
DK1661569T3 (da) 2008-09-15
ES2285341T3 (es) 2007-11-16
EP1568367B1 (en) 2007-04-18
HUP0401213A2 (hu) 2004-12-28
EP1695705A1 (en) 2006-08-30
EP1987831A1 (en) 2008-11-05
ATE334678T1 (de) 2006-08-15
EP1568367A1 (en) 2005-08-31
CN101492416A (zh) 2009-07-29
ES2312050T3 (es) 2009-02-16
CN1568185A (zh) 2005-01-19
MXPA04001500A (es) 2004-05-14
CN101492416B (zh) 2012-02-22
EP1529530B1 (en) 2006-08-02
DK1568367T3 (da) 2007-07-30
DK1568367T5 (da) 2009-11-23
ES2270263T7 (es) 2010-03-31
KR100920439B1 (ko) 2009-10-08
EP1674097B1 (en) 2008-06-11
PT1661569E (pt) 2008-08-18
SI1669068T1 (sl) 2008-10-31
RU2329043C9 (ru) 2008-11-20
JP4441446B2 (ja) 2010-03-31
SI1529530T1 (sl) 2006-12-31
KR20040030125A (ko) 2004-04-08
HUP0401213A3 (en) 2011-03-28
JP2005320343A (ja) 2005-11-17
ATE403427T1 (de) 2008-08-15
DE60226914D1 (de) 2008-07-10
EP1669068A1 (en) 2006-06-14
CY1108276T1 (el) 2014-02-12
DE60219698T2 (de) 2007-12-27
IL203923A (en) 2013-03-24
DE60213678T3 (de) 2010-02-25
HK1090291A1 (en) 2006-12-22

Similar Documents

Publication Publication Date Title
IL160219A0 (en) Compounds effecting glucokinase
AU2002349297A8 (en) Statin-like compounds
GB0126433D0 (en) Compounds
GB0101996D0 (en) Organtic compounds
GB0102668D0 (en) Compounds
GB0112324D0 (en) Compounds
GB0102665D0 (en) Compounds
GB0108102D0 (en) Compounds
GB0102673D0 (en) Compounds
GB0115178D0 (en) Compounds
GB0108097D0 (en) Compounds
GB0105098D0 (en) Compounds
GB0106673D0 (en) Compounds
GB0121493D0 (en) Compounds
GB0127431D0 (en) Compounds
GB0102661D0 (en) Compounds
GB0104397D0 (en) Compounds
GB0104396D0 (en) Compounds
GB0104398D0 (en) Compounds
GB0103314D0 (en) Compounds
GB0104399D0 (en) Compounds
GB0104401D0 (en) Compounds
GB0130386D0 (en) Compounds
GB0102670D0 (en) Compounds
GB0130390D0 (en) Compounds

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)